UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer

International journal of cancer, 2016-05, Vol.138 (9), p.2274-2280

2016

Volltextzugriff (PDF)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1

ESMO open, 2021-10, Vol.6 (5), p.100257-100257, Article 100257

2021

Volltextzugriff (PDF)

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

Oncogene, 2014-11, Vol.33 (47), p.5405-5414

2014

Volltextzugriff (PDF)

Tu-be or not tu-be: That is the question… About serous ovarian carcinogenesis

Critical reviews in oncology/hematology, 2013-10, Vol.88 (1), p.134-143

2013

Volltextzugriff (PDF)

Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifen

European journal of histochemistry, 2014-04, Vol.58 (2), p.2251-2251

2014

Volltextzugriff (PDF)

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

ESMO Gastrointestinal Oncology, 2024-09, Vol.5, p.100084, Article 100084

2024

Volltextzugriff (PDF)

Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii38-viii39

2018

Volltextzugriff (PDF)

Conception et validation préclinique de nanobodies radiomarqués dirigés contre HER3 dans le cancer du sein triple négatif

Médecine nucléaire : imagerie fonctionelle et métabolique, 2021-07, Vol.45 (4), p.181-181

2021

Volltextzugriff (PDF)

Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy

Anticancer research, 2022-07, Vol.42 (7), p.3583-3594

2022

Volltextzugriff (PDF)

Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial

Cancers, 2023-03, Vol.15 (7), p.2030

2023

Volltextzugriff (PDF)

Évaluation préclinique du 18F-ML10, radiotraceur de l’apoptose, dans des modèles de cancer du sein triple négatif

Médecine nucléaire : imagerie fonctionelle et métabolique, 2019-03, Vol.43 (2), p.210-211

2019

Volltextzugriff (PDF)

444P Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer

Annals of oncology, 2021-09, Vol.32, p.S556-S556

2021

Volltextzugriff (PDF)

Analyse peropératoire et définitive du ganglion sentinelle (GS), classification de l'atteinte ganglionnaire : Cancer du sein et aires ganglionnaires: quoi de neuf en 2013 ?

Oncologie (Paris, France), 2013, Vol.15 (6), p.299-303

2013

Volltextzugriff (PDF)

Analyse peropératoire et définitive du ganglion sentinelle (GS), classification de l’atteinte ganglionnaire

Oncologie (Paris, France), 2013-06, Vol.15 (6), p.299-303

2013

Volltextzugriff (PDF)

9INBIOMARKERS OF RESIDUAL DISEASE: THE CLASSICS AND THE NEW DISCOVERIES

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv5-iv5

2014

Volltextzugriff (PDF)

Biomarkers of Residual Disease: the Classics and the New Discoveries

Annals of oncology, 2014-09, Vol.25, p.iv5

2014

Volltextzugriff (PDF)

Abstract P2-09-29: Potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy, revealed by genomic analyses and assessment of tumor-infiltrating lymphocytes

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-09-29

2018

Volltextzugriff (PDF)

Abstract P5-12-09: The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-12-09

2019

Volltextzugriff (PDF)

Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy

Annals of oncology, 2017-09, Vol.28, p.v607-v607

2017

Volltextzugriff (PDF)

Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history

Annals of oncology, 2019-12, Vol.30, p.xi7

2019

Volltextzugriff (PDF)

Abstract P4-15-03: Tumor-infiltrating lymphocytes in breast ductal carcinoma in situ: Correlations with tumor pathobiology in a French cohort of 495 cases (BONBIS)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-15-03

2018

Volltextzugriff (PDF)

123PGene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Abstract P6-04-06: Transcriptome analysis reveals possible therapeutic targets in a non-immunogenic, mesenchymal-type triple negative breast cancer, resistant to anti-EGFR/cytoxics-based neoadjuvant treatment: A pilot study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-04-06

2016

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(38)

Sprache

Englisch
(30)
Französisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer

Refining patient selection for breast cancer immunotherapy: beyond PD-L1

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

Tu-be or not tu-be: That is the question… About serous ovarian carcinogenesis

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifen

The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)

Conception et validation préclinique de nanobodies radiomarqués dirigés contre HER3 dans le cancer du sein triple négatif

Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy

Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial

Évaluation préclinique du 18F-ML10, radiotraceur de l’apoptose, dans des modèles de cancer du sein triple négatif

444P Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer

Analyse peropératoire et définitive du ganglion sentinelle (GS), classification de l'atteinte ganglionnaire : Cancer du sein et aires ganglionnaires: quoi de neuf en 2013 ?

Analyse peropératoire et définitive du ganglion sentinelle (GS), classification de l’atteinte ganglionnaire

9INBIOMARKERS OF RESIDUAL DISEASE: THE CLASSICS AND THE NEW DISCOVERIES

Biomarkers of Residual Disease: the Classics and the New Discoveries

Abstract P2-09-29: Potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy, revealed by genomic analyses and assessment of tumor-infiltrating lymphocytes

Abstract P5-12-09: The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer

Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy

Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history

Abstract P4-15-03: Tumor-infiltrating lymphocytes in breast ductal carcinoma in situ: Correlations with tumor pathobiology in a French cohort of 495 cases (BONBIS)

123PGene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)

Abstract P6-04-06: Transcriptome analysis reveals possible therapeutic targets in a non-immunogenic, mesenchymal-type triple negative breast cancer, resistant to anti-EGFR/cytoxics-based neoadjuvant treatment: A pilot study

Suchergebnisse filtern